SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" ($CAW.X) crypto is trending as its community rallies behind the meme coin, emphasizing its multi-chain presence and deflationary mechanisms. Active discussions highlight the strength of the community and the potential for significant gains. The coin's presence on multiple chains like Solana, BSC, Cronos, and ETH (Base) is a key talking point.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to positive Phase 2 trial data for its drug sonelokimab in treating hidradenitis suppurativa, leading to raised price targets and speculation about its potential as a best-in-class treatment. The community is actively discussing the implications of this data, especially compared to competitors, and the possibility of a future buyout. Some investors believe MLTX is thoroughly de-risked.

WeRide, Inc. is a holding company, which engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers, and related sensor suites. The company was founded by Tony Xu Han and Yan Li on March 13, 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide ($WRD) is trending due to positive Q2 earnings, highlighting significant robotaxi revenue growth and expanded global operations, including a new permit in Saudi Arabia. The community is discussing the partnership with Bosch for mass production of ADAS systems and upcoming collaboration with UBER and GRAB, though some express frustration with the stock's price action despite the positive news.

BRETT the dancer, gamer, and cultural icon of BASE chain (some like to call me the PEPE of BASE).

Brett

BRETT.X is trending as the community debates its potential amidst discussions about a potential breakout and comparisons to other cryptocurrencies like JTRAMBO and TOSHI.X.  Some traders are buying the dips and expressing long-term bullish sentiment, while others are skeptical, citing concerns about market cap and exchange listings. Conversations also mention potential catalysts and technical analysis pointing to possible upside.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas ($PANDU.X) is trending as the community discusses its potential, recent listing on MEXC, and comparisons to other tokens like $PENGU.X. Some users are pointing to its NFT ranking and on-chain fundamentals, while others are debating wallets and entry points.

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Insmed Inc

Insmed ($INSM) is trending amid community excitement surrounding positive data and potential FDA approval of Brensocatib for bronchiectasis, with some analysts projecting blockbuster status and a buyout. Discussions also involve the potential of TPIP and a possible expansion into new indications. Community members are closely watching upcoming presentations and potential impacts on competitors like $UTHR.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending, and the community is actively engaging with the classic "What's UpDog?" joke, driving social volume. Some users are pointing out the project has been live on Solana for over a year and has a locked and burned LP. Others suggest the recent increase in social volume is due to only one or two accounts.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI.X is trending as the community emphasizes its importance as the tokenized representation of Satoshi Nakamoto, the pseudonymous creator of Bitcoin. Community members are actively discussing its potential as a cultural icon within the crypto industry, highlighting the 'We are all Satoshi' movement and its never-fading narrative.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

$BOB.X is trending as community members discuss its capped supply and upcoming halving, drawing comparisons to $BTC.X and its potential within web3. Some users are highlighting its availability on multiple chains and mining via $ICP.X, while others are comparing it to other meme coins.

ProShares Trust - ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF

VIXY is trending as traders monitor rising volatility, influenced by factors like rising long-term rates, potential bubble bursts, and geopolitical tensions (war on deck). Community members are actively discussing downside protection strategies and hedging portfolios with volatility-linked instruments. Some traders believe yearly charts point to significant moves ahead, while others note VIXY's potential disconnect from the VIX.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 0.00% and +14.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy?

Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates

Aclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered into a licensing deal with Biosion for rights for two antibody products and announced an $80 million funding, lifting retail sentiment.Aclaris is focused on developing drugs to treat immuno-inflammatory diseases. The exclusive license agreement with Biosion includes worldwide rights (excluding Greater China) to BSI-045B, a clinical-stage, novel anti-TSLP monoclonal antibody; and BSI-502, a pre-clinical stage novel bispecific antibody directed against “both TSLP and IL4R,” used to treat conditions like atopic dermatitis. &nbsp;The private placement includes over 35.55 million shares of common stock at a purchase price of $2.25 per share. The placement is expected to close on or about Nov. 19, 2024, subject to customary closing conditions.Vivo Capital led the funding, with participation from new and existing investors including Forge Life Science Partners, Rock Springs Capital, RA Capital Management, Adage Capital Partners LP, Decheng Capital, Logos Capital and Samsara BioCapital.Several brokerages have revised their ratings for Aclaris following the news. Leerink upgraded Aclaris to ‘Outperform’ from ‘Market Perform’ with its price target raised to $7 from $2. The firm cited completion of the company's strategic review, and expects investor focus to shift to its "newly strengthened" immunology-focused pipeline that includes the two in-licensed biologics from discovery-focused Biosion - BSI-045B and BSI-502, The Fly.com <a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/">reported.</a>Jefferies also upgraded Aclaris to ‘Buy’ from ‘Hold’ with a price target of $7, up from $2.Meanwhile, Piper Sandler upgraded the company to ‘Overweight’ from ‘Neutral’ with a price target of $13, up from $3.Retail sentiment moved from ‘neutral’ (47/100) to ‘extremely bullish’(96/100); message volumes rose to ‘extremely high’ levels from ‘normal’.<figure class="image"><img style="aspect-ratio:1304/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_19_at_9_24_37_PM_b73837e53c.png" alt="Screenshot 2024-11-19 at 9.24.37 PM.png" width="1304" height="290"><figcaption>ACRS sentiment and message volumes on Nov 19 as of 10:55 am ET| Source: Stocktwits</figcaption></figure>“This transformative transaction, which marks the completion of our strategic review process, accelerates our evolution into becoming a leading immunology company with both small and large molecule drugs," Neal Walker, interim CEO and chair of Aclaris, said in a statement.Net proceeds from the capital raise are expected to fund the research and development of its drug pipeline and for general corporate purposes.Aclaris stock is up 300% year-to-date.For updates and corrections, email newsroom@stocktwits.com &nbsp;&nbsp;

Net proceeds from the capital raise are expected to fund the research and development of its drug pipeline| Picture source: pexels

Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment Jumps

Leerink upgraded Aclaris to ‘Outperform’ from ‘Market Perform’ with its price target raised to $7 from $2; Piper Sandler upgraded the company  to ‘Overweight’ from ‘Neutral.’ 

Equity

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets Biosion Announces Exclusive, Global License...

H.C. Wainwright Reaffirms Their Hold Rating on Aclaris Therapeutics (ACRS)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Aclaris Therapeutics (ACRS Research Report). The compa...

Aclaris Therapeutics Secures Deal with OMERS for OLUMIANT Royalties

Aclaris Therapeutics (ACRS) has provided an update. Aclaris Therapeutics has struck a lucrative deal with OMERS, selling a portion of its future ro...

Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Aclaris Therapeutics Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$1.99
Prev Close	$1.87
Open	$1.90
Dividend Yield	0.00%
50-Day Moving Average	$1.79
Beta	1.09
Avg. Volume	743,962.05
PE Ratio	-1.45

52-Week High	$5.17
52-Week Low	$1.05
Market Capitalization	$215.58M
EPS (Annual)	-$1.71
Price to Book	1.64
Revenue Per Employee	$292,500.00
Enterprise Value/EBITDA	N/A

ACRS
Aclaris Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACRS News

ACRS Aclaris Therapeutics Inc